The 10 most recent market catalysts affecting $ATRC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 65
AtriCure Management Discusses Strategic Growth and Financial Outlook at UBS Global Healthcare Conference
AtriCure management presented at the UBS Global Healthcare Conference, discussing the adoption of its EnCompass system and expansion of pain management solutions. The company outli…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 65
Needham Raises Price Target on AtriCure to $70 From $64, Keeps Buy Rating
Needham has raised its price target for AtriCure (ATRC) to $70 from $64 and maintained its 'Buy' rating. This positive revision comes after the company's third-quarter 2026 financi…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Raises AtriCure Price Target to $70
BTIG has raised its 12-month price target for AtriCure (ATRC) to $70 from $63, maintaining a Buy rating. This action signals increased confidence from the analyst firm in AtriCure'…
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 65
Citizens Raises Price Target on AtriCure to $68.00
Citizens, an investment firm, has raised its price target on AtriCure (ATRC) shares from $52.00 to $68.00, while reiterating a 'Market Outperform' rating. This upgrade signals incr…
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on AtriCure, Raises Price Target to $63
BTIG analyst Ryan Zimmerman has raised the price target for AtriCure (ATRC) from $55 to $63 while maintaining a 'Buy' rating. This action indicates a strengthened positive outlook …
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on AtriCure, Raises Price Target to $64
Needham analyst Mike Matson has maintained a 'Buy' rating on AtriCure (ATRC) and raised the price target from $45 to $64. This is a positive development for ATRC as it indicates in…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Maintains Overweight on AtriCure, Raises Price Target to $60
This 8-K filing discloses that Piper Sandler analyst Matt O'Brien has maintained an 'Overweight' rating on AtriCure (ATRC) and raised its price target from $50 to $60. This is sign…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on AtriCure, Raises Price Target to $55
BTIG analyst Marie Thibault maintained a 'Buy' rating on AtriCure (ATRC) and raised the price target from $45 to $55. This indicates increased confidence from the analyst in the co…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 75
AtriCure Raises FY2026 GAAP EPS Guidance from $0.00-$0.04 to $0.05-$0.13 vs $0.05 Est
AtriCure (ATRC) announced an upward revision to its fiscal year 2026 GAAP EPS guidance, moving from a range of $0.00-$0.04 to $0.05-$0.13. This is a significant development as the …
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
AtriCure Q2 Adj. EPS $0.18 Beats $0.00 Estimate, Sales $153.600M Beat $151.842M Estimate
AtriCure (ATRC) reported Q2 adjusted EPS of $0.18, which not only beat the analyst consensus of $0.00 but also marked a significant improvement from a loss of $(0.02) per share in …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.